Point72 Asset Management L.P. Sells 232,561 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

Point72 Asset Management L.P. trimmed its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 90.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,758 shares of the company’s stock after selling 232,561 shares during the quarter. Point72 Asset Management L.P.’s holdings in Astrana Health were worth $1,434,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ASTH. GAMMA Investing LLC bought a new stake in shares of Astrana Health during the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC bought a new position in Astrana Health in the 3rd quarter worth about $35,000. KBC Group NV bought a new position in Astrana Health in the 3rd quarter worth about $70,000. Quest Partners LLC bought a new position in Astrana Health in the 3rd quarter worth about $133,000. Finally, Central Pacific Bank Trust Division bought a new position in Astrana Health in the 3rd quarter worth about $160,000. 52.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ASTH shares. KeyCorp started coverage on Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. BTIG Research upped their target price on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. TD Cowen started coverage on Astrana Health in a research note on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. Finally, Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $65.17.

Astrana Health Price Performance

ASTH opened at $39.47 on Wednesday. The stock has a 50-day moving average price of $50.76 and a 200-day moving average price of $48.18. Astrana Health, Inc. has a 12-month low of $32.32 and a 12-month high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $2.22 billion, a P/E ratio of 30.36, a PEG ratio of 1.94 and a beta of 1.14.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the prior year, the business posted $0.47 EPS. Equities analysts predict that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.